Form 3/A - Initial statement of beneficial ownership of securities: [Amend]
SEC Accession No. 0000950170-25-084490
Filing Date
2025-06-10
Accepted
2025-06-10 17:31:03
Documents
1
Period of Report
2025-06-05

Document Format Files

Seq Description Document Type Size
1 3/A ownership.html 3/A  
1 3/A ownership.xml 3/A 3990
  Complete submission text file 0000950170-25-084490.txt   5424
Mailing Address C/O SYNDAX PHARMACEUTICALS, INC. 400 TOTTEN POND ROAD, SUITE 110 WALTHAM MA 02451
Business Address
Morrison Briggs (Reporting) CIK: 0001654430 (see all company filings)

Type: 3/A | Act: 34 | File No.: 001-37923 | Film No.: 251038205

Mailing Address BAARERSTRASSE 14 ZUG V8 CH-6300
Business Address BAARERSTRASSE 14 ZUG V8 CH-6300 6173154600
CRISPR Therapeutics AG (Issuer) CIK: 0001674416 (see all company filings)

EIN.: 473173478 | State of Incorp.: V8 | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)